There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kronos Bio (KRON – Research Report), Jazz Pharmaceuticals (JAZZ – Research Report) and KalVista Pharmaceuticals (KALV – Research Report) with bullish sentiments.
Kronos Bio (KRON)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Kronos Bio today and set a price target of $2.25. The company’s shares closed last Thursday at $1.03.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
Kronos Bio has an analyst consensus of Strong Buy, with a price target consensus of $4.13.
See Insiders’ Hot Stocks on TipRanks >>
Jazz Pharmaceuticals (JAZZ)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Jazz Pharmaceuticals, with a price target of $200.00. The company’s shares closed last Thursday at $109.29, close to its 52-week low of $106.61.
According to TipRanks.com, Livnat is a 2-star analyst with an average return of
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $186.58, implying a 77.5% upside from current levels. In a report issued on April 23, Barclays also maintained a Buy rating on the stock with a $230.00 price target.
KalVista Pharmaceuticals (KALV)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on KalVista Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Thursday at $12.17.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $31.33, implying a 156.2% upside from current levels. In a report issued on May 1, Needham also maintained a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KRON:
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
- Kronos Bio reports Q4 EPS (43c), consensus (52c)
- KRON Earnings this Week: How Will it Perform?
